Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

4.7K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
4.7K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.9K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

440
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-induced osteomalacia: a 2026 update.

Minerva medica·2026
Same author

Prevalence, predictors, and clinical impact of vitamin D deficiency on 12-month outcomes in hip fracture patients.

Journal of endocrinological investigation·2026
Same author

Exploring the dynamics of FGF23 in patients with Hereditary Hemochromatosis type I following iron depletive treatment: a pilot study.

Journal of endocrinological investigation·2026
Same author

Long-term treatment with denosumab in patients with celiac disease and osteoporosis at high risk of fracture: a retrospective study.

Internal and emergency medicine·2026
Same author

Burosumab treatment for children younger than 12 months with X-linked hypophosphataemia.

The lancet. Diabetes & endocrinology·2026
Same author

ADAR2 induces the differentiation of osteosarcoma cells by editing activity on IGFBP7: new implications for therapy.

Bone research·2026

Related Experiment Video

Updated: Apr 29, 2026

Mouse Round Spermatid Injection
08:41

Mouse Round Spermatid Injection

Published on: January 26, 2024

1.7K

Romosozumab: from basic to clinical aspects.

Salvatore Minisola1

  • 1"Sapienza" Rome University, Department of Internal Medicine and Medical Disciplines , Via del Policlinico 155, 00161 Rome , Italy +39 06 49978388 ; +39 06 49978365 ; salvatore.minisola@fastwebnet.it.

Expert Opinion on Biological Therapy
|May 20, 2014
PubMed
Summary
This summary is machine-generated.

Sclerostin inhibition by romosozumab, a monoclonal antibody, promotes bone formation and increases bone mineral density. This anabolic action shows promise for osteoporosis treatment.

Keywords:
anabolic therapyosteoporosisromosozumabsclerostin

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Related Experiment Videos

Last Updated: Apr 29, 2026

Mouse Round Spermatid Injection
08:41

Mouse Round Spermatid Injection

Published on: January 26, 2024

1.7K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Area of Science:

  • Bone biology and endocrinology.
  • Pharmacology of monoclonal antibodies.

Background:

  • The Wnt signaling pathway is crucial for bone formation.
  • Sclerostin inhibits the Wnt pathway and is a target for increasing bone mass.

Discussion:

  • Romosozumab, a sclerostin-targeting antibody, demonstrated anabolic effects in preclinical and early human studies.
  • Observed increases in bone mineral density align with animal model findings.

Key Insights:

  • Inhibiting sclerostin with romosozumab enhances bone formation.
  • This antibody therapy leads to significant improvements in bone mineral density.

Outlook:

  • Further large-scale studies with fracture endpoints are needed.
  • Romosozumab may become a pivotal therapeutic agent for osteoporosis management.